On the fly News and insights, exclusive to thefly.com

ALKS

Alkermes

$42.53

-0.43 (-1.00%)

07:04
04/16/18
04/16
07:04
04/16/18
07:04

FDA rescinds Refusal to File letter for Alkermes depression drug

Alkermes announced this morning that the FDA accepted for review the New Drug Application for ALKS 5461, an oral investigational medicine for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard antidepressant therapies. FDA's target action date for the ALKS 5461 NDA is Jan. 31, 2019. "FDA's acceptance of the ALKS 5461 NDA and rescission of the Refusal to File letter issued March 30, 2018 follows productive interactions with the Agency in which Alkermes clarified certain aspects of the NDA submission. No additional data or analyses were submitted by Alkermes to FDA," the company said in a statement. Shares of Alkermes fell 22% on April 2 on news that the company received a Refusal to File letter from the FDA for ALKS 5461. The stock closed Friday down 43c to $42.53.

  • 08

    May

  • 21

    May

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.